IMAC Holdings, Inc. (NASDAQ: IMAC) is a diversified health and wellness company providing a comprehensive suite of medical, aesthetic, regenerative and rehabilitative services. Operating through a network of strategically located clinics across the United States, the company specializes in minimally invasive treatments designed to enhance hair restoration, cosmetic appearance, tissue regeneration and musculoskeletal recovery. IMAC’s integrated platform allows patients to receive tailored care plans that combine technology-driven procedures with personalized medical oversight.
The company’s core offerings include advanced hair restoration solutions such as Follicular Unit Extraction (FUE) systems, platelet-rich plasma (PRP) therapies and laser-based treatments. In the aesthetic segment, IMAC clinics deliver injectables, dermal fillers, non-surgical skin tightening and body contouring services. On the regenerative side, the company utilizes autologous cellular therapies—including PRP and stem cell platforms—to support wound healing, joint repair and anti-aging protocols. Complementing these services is a physical therapy and rehabilitation division that covers orthopedic, neurological and sports-related recovery programs.
Founded in 2018 by a team of healthcare entrepreneurs and clinicians, IMAC has pursued a growth strategy centered on clinic partnerships, brand extensions and targeted market entry into high-demand regions. Since its initial public listing on the NASDAQ exchange, the company has expanded its footprint beyond its Southeast origins into key metropolitan areas in Texas, Colorado and the Midwest. This expansion has been bolstered by collaborations with managed care organizations and specialty referral networks, positioning IMAC to capitalize on rising demand for out-patient, non-invasive care solutions.
Under the leadership of President and Chief Executive Officer Anthony Falcinelli, IMAC is governed by a board of directors with deep expertise in healthcare operations, medical technology and corporate finance. The management team emphasizes scalable growth through disciplined capital allocation, investments in proprietary treatment protocols and digital patient-engagement platforms. Looking ahead, the company aims to broaden its service offerings, enhance clinical outcomes through data analytics and pursue both organic openings and select acquisitions to drive long-term shareholder value.
AI Generated. May Contain Errors.
